Evidence map›Paper›PMID 32035018›Full record

ArticleLancet (London, England)2020

Reducing mortality from 2019-nCoV: host-directed therapies should be an option.

Alimuddin Zumla, David S Hui, Esam I Azhar, Ziad A Memish, Markus Maeurer

3 registry-linked trialsAbstract readLetter
In one paragraph

Article in Lancet (London, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 251 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
251citing papers in PubMed, 7 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04322188 completednot on this map

An Observational Study of the Use of Siltuximab (SYLVANT) in Patients Diagnosed With COVID-19 Infection Who Have Developed Serious Respiratory Complications

TypeobservationalSponsorA.O. Ospedale Papa Giovanni XXIIIRan2020 to 2020Enrolled220ConditionsSevere Acute Respiratory Syndrome (ARDS) Secondary to SARS-COV-2 Infection
NCT04332042 phase2unknown statusnot on this map

TOFAcitinib in Patients With Early Onset SARS-CoV2 Interstitial Pneumonia

TypeinterventionalSponsorUniversità Politecnica delle MarcheRan2020 to 2020Enrolled50ConditionsSARS-COv2 Related Interstitial PneumoniaArmsTofacitinib
NCT04517162 phase1 / phase2unknown statusnot on this map

Effect of Collagen-Polyvinylpyrrolidone for the Treatment of Hyperinflammation and the Pulmonary Fibrosis in COVID-19 Patients. Double Blind Placebo-controlled Pilot Trial

TypeinterventionalSponsorJanette Furuzawa CarballedaRan2020 to 2021Enrolled90ConditionsCovid19, Cytokine Storm, Regulation of Inflammatory Response, Pulmonary FibrosisArmsCollagen-Polyvinylpyrrolidone
3 · Its place in the literature

Who cites it

251 citing papers in PubMed, 7 syntheses or guidelines pooled it.

  1. Pooled it
  2. Associations between Serum Interleukins (IL-1BioMed research international · 2022
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Review
  10. Article
  11. Exploration of shared gene signatures and molecular mechanisms between psoriasis and COVID-19: evidence from transcriptome data.Mammalian genome : official journal of the International Mammalian Genome Society · 2026
    Article
  12. Article
  13. Article
  14. Mucosal-associated invariant T-cells in pulmonary pathophysiology.Current opinion in pulmonary medicine · 2025
    Review
  15. Article
  16. Observational
  17. Article
  18. Article
  19. Article
  20. Article

191 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Alimuddin ZumlaDepartment of Infection, Division of Infection and Immunity, University College London, London, UK; National Institute for Health Research Biomedical Research Centre, University College London Hospitals NHS Foundation Trust, London, UK.
David S HuiDepartment of Medicine & Therapeutics, Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong, China.
Esam I AzharSpecial Infectious Agents Unit, King Fahd Medical Research Center and Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia.
Ziad A MemishInfectious Diseases Division, Department of Medicine and Research Department, Prince Mohamed Bin Abdulaziz Hospital, Ministry of Health, Riyadh, Saudi Arabia; College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
Markus MaeurerImmunotherapy Programme, Champalimaud Centre for the Unknown, 1400-038 Lisbon, Portugal; I Med Clinic, University of Mainz, Mainz, Germany. Electronic address: markus.maeurer@fundacaochampalimaud.pt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

BetacoronavirusCoronavirus InfectionsCOVID-19COVID-19 Drug TreatmentCOVID-19 SerotherapyDrug DiscoveryGlobal HealthHumansImmunization, PassivePandemicsPneumonia, ViralSARS-CoV-2

Identifiers

PMID32035018
PMCPMC7133595

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.